Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 4D Molecular Therapeutics Inc (NQ: FDMT ) 8.350 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about 4D Molecular Therapeutics Inc < Previous 1 2 3 Next > 4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference September 23, 2024 Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day September 18, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm September 17, 2024 From Kaskela Law LLC Via Business Wire FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm September 12, 2024 From The Schall Law Firm Via Business Wire 4DMT Announces Presentations at Upcoming Retina Conferences September 05, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in the 2024 Cantor Global Healthcare Conference September 03, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 August 27, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference August 12, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights August 08, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board August 05, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings July 29, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire 4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings July 21, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm July 17, 2024 From The Schall Law Firm Via Business Wire 4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity July 17, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy June 24, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast June 18, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting June 08, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference June 06, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting June 04, 2024 • 24-week injection-free subgroup analyses from the Randomized Phase 2 Dose Expansion Stage of PRISM Trial Evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden... From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in Upcoming Investor Conferences June 03, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference May 30, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights May 09, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in Upcoming Investor Conference May 07, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Announces Presentations at ARVO 2024 Annual Meeting May 01, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis March 28, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in Upcoming Investor Conferences March 04, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Reports Full Year 2023 Financial Results and Operational Highlights February 29, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024 February 12, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock February 06, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock February 05, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
